ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.96
0.71%
US Tech 100
20,762.73
1.73%
S&P 500
5,942.47
1.26%
US Dollar vs CAD
1.44434
0.02%
Bitcoin
98,216.25
-0.09%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Cytokinetics Inc (CYTK)

  7. Cytokinetics Inc (CYTK) News

CYTK

Cytokinetics (CYTK)

Cytokinetics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CYTK
DateTimeSourceHeadlineSymbolCompany
01/03/20253:00PMGlobeNewswire Inc.Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:CYTKCytokinetics Inc
12/23/20246:30AMGlobeNewswire Inc.Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathyNASDAQ:CYTKCytokinetics Inc
12/19/202411:00PMGlobeNewswire Inc.Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater ChinaNASDAQ:CYTKCytokinetics Inc
12/16/20246:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
12/16/20243:38PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTKCytokinetics Inc
12/16/20243:13PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
12/12/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
12/10/20244:42PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
12/10/20243:06PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
12/05/20243:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
12/05/20243:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
12/05/20243:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
12/05/20243:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
12/05/20243:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
12/03/20243:00PMGlobeNewswire Inc.Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CYTKCytokinetics Inc
12/03/20246:30AMGlobeNewswire Inc.Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection FractionNASDAQ:CYTKCytokinetics Inc
12/02/20245:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
12/02/20243:01PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
12/02/20243:00PMGlobeNewswire Inc.Cytokinetics to Participate in December Investor ConferencesNASDAQ:CYTKCytokinetics Inc
12/02/20246:30AMGlobeNewswire Inc.Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathyNASDAQ:CYTKCytokinetics Inc
11/26/20246:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
11/26/20244:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
11/26/20243:09PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
11/25/20243:10PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
11/19/20243:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
11/19/20245:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTKCytokinetics Inc
11/19/20241:30AMGlobeNewswire Inc.Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in JapanNASDAQ:CYTKCytokinetics Inc
11/18/20243:31PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
11/16/20248:00AMGlobeNewswire Inc.Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024NASDAQ:CYTKCytokinetics Inc
11/16/20248:00AMGlobeNewswire Inc.Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024NASDAQ:CYTKCytokinetics Inc
 Showing the most relevant articles for your search:NASDAQ:CYTK

Your Recent History

USOTC
LEHNQ
Lehman Brothers Financial (CE)
USOTC
HIRU
Hiru (PK)
USOTC
TWOH
Two Hands (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
RDGL
Vivos (QB)
USOTC
FNMA
Fannie Mae (QB)
USOTC
HMBL
HUMBL (PK)
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
WDLF
Decentral Life (PK)
USOTC
DBMM
Digital Brand Media and ... (PK)
NASDAQ
LWLG
Lightwave Logic
USOTC
BIEL
Bioelectronics (PK)
NASDAQ
COOP
Mr Cooper
NASDAQ
AMRN
Amarin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads